Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation (NASDAQ: BCPC) is a global specialty ingredient manufacturer for health and nutrition markets, and its news flow reflects this focus. Company press releases highlight the development, manufacture and marketing of specialty ingredients that improve and enhance the health and well-being of life on the planet, as well as financial and corporate updates relevant to investors and industry observers.
Visitors to this BCPC news page can review Balchem’s announcements on quarterly financial results, dividend declarations and participation in investor conferences. Recent releases have reported segment-level performance for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments, along with measures such as net sales, earnings from operations, adjusted EBITDA and free cash flow, as described in accompanying Form 8-K filings.
Balchem also issues news related to regulatory and trade developments that affect its markets. For example, the company joined another EU producer in welcoming European Union anti-dumping duties on choline chloride imports from China, emphasizing the importance of fair trade for the EU food and feed supply chain and for maintaining a healthy domestic choline chloride industry.
In addition, Balchem regularly announces its participation in conferences hosted by firms such as CJS Securities, Baird, H.C. Wainwright, Wells Fargo and others, where its leadership presents to the investment community. These updates provide insight into how the company communicates its strategy and segment performance to shareholders and analysts. Investors and researchers can use this news stream to follow Balchem’s financial reporting, capital allocation decisions such as dividends, and its commentary on market and regulatory conditions affecting its human nutrition, animal nutrition and specialty products businesses.
Balchem (NYSE:BCPC) launched the Metalosate® T.E.A.M.™ digital plant tissue analysis platform on March 9, 2026 to translate tissue data into actionable micronutrient recommendations for specialty crops. Free for U.S. pest control advisors and agronomists, T.E.A.M. evaluates nutrient concentrations versus crop-specific optimal ranges and archives historical data for trend tracking.
Balchem (NASDAQ: BCPC) will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Company executives Ted Harris (Chairman, President & CEO), Martin Bengtsson (CFO) and Allison Baurichter (Senior Director Investor Relations) will attend and speak.
Balchem (NASDAQ: BCPC) will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Senior management attendees include Ted Harris (Chairman, President & CEO), Martin Bengtsson (CFO) and Allison Baurichter (Senior Director, Investor Relations).
The company will present and engage with investors at the industry conference, offering updates on strategy and market positioning for health and nutrition ingredients.
Balchem (NASDAQ: BCPC) reported fourth-quarter and full-year 2025 results on Feb 20, 2026, with record full-year net sales of $1.037 billion and record adjusted EBITDA of $274.9 million. Fourth-quarter net sales were $263.6 million and GAAP net earnings were $39.2 million.
The company reported record 2025 free cash flow of $173.6 million, diluted GAAP EPS of $4.75 for the year, and said it raised its dividend by a double-digit percentage.
Balchem (NASDAQ: BCPC) will host a conference call on February 20, 2026 at 11:00 AM ET to review fourth quarter and full year 2025 results. Results and financial exhibits will be published prior to market open that day and posted on the company website.
The live webcast and replay will be available at the provided Q4 Events link; dial‑in details and Conference ID 4400943 are available for investors and analysts.
Balchem (NASDAQ: BCPC) will participate in the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026. Company representatives attending include Ted Harris (chairman, president and CEO), Martin Bengtsson (CFO) and Allison Baurichter (senior director, investor relations). The virtual presentation provides an opportunity for management to discuss strategy and engage with investors.
Balchem (NASDAQ:BCPC) and Eastman welcomed the EU decision published on Dec 19, 2025 to impose anti-dumping duties of 90.0%–115.9% on choline chloride imports from China, effective for five years with possible renewal.
The producers say the measures protect EU food and feed supply chains, preserve jobs, support continued EU investment and innovation, and ensure supply stability and high health and safety standards. The statement also notes revised customs origin rules clarifying that liquid choline chloride retains Chinese origin if the key chemical reaction occurred in China, helping prevent circumvention.
Balchem (NASDAQ: BCPC) announced that on Dec 9, 2025 its board declared an annual dividend of $0.96 per share, payable Jan 20, 2026 to holders of record at the close of business on Dec 23, 2025.
The dividend equals a 10.3% increase versus last year and marks the seventeenth consecutive annual dividend increase, which management links to sustained financial performance and board confidence in long-term strategy.
Balchem (NASDAQ: BCPC) will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025. Key speakers scheduled are Ted Harris (Chairman, President & CEO), Martin Bengtsson (CFO) and Allison Baurichter (Senior Director Investor Relations).
The presentation signals management engagement with investors at a major industry conference; no financial data, times, or webcast details were provided.
Balchem (NASDAQ: BCPC) reported third quarter fiscal 2025 results for the period ended September 30, 2025: net sales $267.6M (up 11.5% vs. prior year), net earnings $40.3M (up 19.1%), adjusted EBITDA $71.4M (up 11.0%), and free cash flow $50.7M. Cash from operations was $65.6M. Net debt was reduced to $88.9M with a leverage ratio of 0.3x. The Human Nutrition and Health segment reported record sales of $174.1M (up 14.3%).
Recent milestones include approvals to build a new microencapsulation facility in Orange County, NY, and five new sponsored research studies published in the quarter, including a choline biomarker study.